Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold
Ask for high quality link by putting your email below
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
We were really happy to participate in SLAS2019 in Washington last week. In addition to spending a few relaxing days in Washington, we enjoyed the warm welcome of the US team of Molecular Devices. We Read more…
HCS Pharma is one of the winner of the Lab’StartUp village, organized by Forum Labo! As such, we have won a stand in the heart of the forum (March 26-28, 2019)… Thanks a lot to Read more…
Extracellular matrix (ECM) is known to have an influence on physiological processes and on tumour progression: ECM properties (composition, stiffness) modulate cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT). For example, EMT is inhibited by Read more…
1 Comment
SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm
[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]